- Home
- AZ vs MRKR Comparison
AZ vs MRKR Comparison
Compare AZ & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AZ
- MRKR
- Stock Information
- Founded
- AZ 2018
- MRKR N/A
- Country
- AZ Canada
- MRKR United States
- Employees
- AZ N/A
- MRKR N/A
- Industry
- AZ Industrial Machinery/Components
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- AZ Industrials
- MRKR Health Care
- Exchange
- AZ Nasdaq
- MRKR Nasdaq
- Market Cap
- AZ 36.4M
- MRKR 35.8M
- IPO Year
- AZ N/A
- MRKR N/A
- Fundamental
- Price
- AZ $6.94
- MRKR $3.10
- Analyst Decision
- AZ
- MRKR Strong Buy
- Analyst Count
- AZ 0
- MRKR 1
- Target Price
- AZ N/A
- MRKR $19.00
- AVG Volume (30 Days)
- AZ 137.2K
- MRKR 25.8K
- Earning Date
- AZ 11-13-2024
- MRKR 11-14-2024
- Dividend Yield
- AZ N/A
- MRKR N/A
- EPS Growth
- AZ N/A
- MRKR N/A
- EPS
- AZ N/A
- MRKR N/A
- Revenue
- AZ $6,628,000.00
- MRKR $5,395,849.00
- Revenue This Year
- AZ $30.95
- MRKR $35.94
- Revenue Next Year
- AZ $646,436.00
- MRKR N/A
- P/E Ratio
- AZ N/A
- MRKR N/A
- Revenue Growth
- AZ N/A
- MRKR 79.04
- 52 Week Low
- AZ $0.85
- MRKR $2.44
- 52 Week High
- AZ $7.00
- MRKR $6.16
- Technical
- Relative Strength Index (RSI)
- AZ 72.93
- MRKR 42.91
- Support Level
- AZ $6.07
- MRKR $2.91
- Resistance Level
- AZ $6.69
- MRKR $3.25
- Average True Range (ATR)
- AZ 0.57
- MRKR 0.38
- MACD
- AZ -0.02
- MRKR -0.11
- Stochastic Oscillator
- AZ 97.22
- MRKR 17.72
About AZ A2Z Smart Technologies Corp.
A2Z Cust2Mate Solutions Corp is engaged in creating shopping carts. With the help of a user-friendly smart algorithm, touch screen, and other technologies, the company streamlines the retail shopping experience by scanning purchased products and enabling in-cart payment so that customers can simply pick & go, and bypass long cashier checkout lines.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.